Trial Profile
A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel (5 mg/g Brimonidine Tartrate) in Patients With Chronic Persistent Vascular Facial Erythema.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2017
Price :
$35
*
At a glance
- Drugs Brimonidine (Primary)
- Indications Erythema
- Focus Therapeutic Use
- Acronyms BR14004
- Sponsors Galderma
- 05 Apr 2017 Status changed from recruiting to completed.
- 09 Aug 2016 New trial record